The group's principal activity is to discover and develop pharmaceutical products. The group is currently pursuing regulatory approval of prestara (TM), its investigational drug for women with systemic lupus erythematosus. It is also pursuing the discovery of antiviral compounds for the treatment of hepatitis c virus ('hcv') infections and is advancing its hcv research program into preclinical development. In addition, the group has established a portfolio of patents and patent applications based on inventions arising from its research and development activities. Trademarks include prestara (TM), anastar (TM) and aslera (TM).
